Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound antihypertensive medicine composition

A composition and drug technology, applied in the field of compound antihypertensive drug composition, can solve the problem that aldosterone receptor antagonists have not received enough attention, and achieve the effect of reducing cardiovascular events, obvious curative effect, and small adverse reactions

Inactive Publication Date: 2017-01-04
SHANGHAI PHARMA DONGYING JIANGSU PHARMA CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Among the major classes of antihypertensive drugs, aldosterone receptor antagonists do not seem to have received enough attention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Perindopril tert-butylamine salt, eplerenone compound tablet and preparation 1

[0050] prescription:

[0051] Element Dosage Perindopril tert-butylamine salt 2mg Eplerenone 25mg lactose 40mg microcrystalline cellulose 25mg Croscarmellose Sodium 2mg Sodium Lauryl Sulfate 2mg Magnesium stearate 1mg silica 1.5mg talcum powder 1.5mg total 100mg

[0052] Preparation:

[0053] (1) Perindopril tert-butylamine salt and eplerenone were mixed with microcrystalline cellulose, lactose and sodium lauryl sulfate in equal increments respectively;

[0054] (2) After mixing, put the above mixture, croscarmellose sodium, silicon dioxide, and talc into the mixer and mix for 30 minutes;

[0055] (3) After shutdown, add magnesium stearate and mix for 15-20 minutes;

[0056] (4) Sampling and testing the content and content uniformity of intermediate products, and tableting;

[0057] (5) Alumi...

Embodiment 2

[0058] Example 2 Perindopril tert-butylamine salt, eplerenone compound tablet and preparation 2

[0059] prescription:

[0060] Element Dosage Perindopril tert-butylamine salt 4mg Eplerenone 25mg lactose 40mg microcrystalline cellulose 25mg Croscarmellose Sodium 2.0mg Sodium Lauryl Sulfate 2.0mg Magnesium stearate 1.0mg silica 0.5mg talcum powder 0.5mg total 100mg

[0061] Preparation:

[0062] (1) Perindopril tert-butylamine salt and eplerenone were mixed with microcrystalline cellulose, lactose and sodium lauryl sulfate in equal increments respectively;

[0063] (2) After mixing, put the above mixture, croscarmellose sodium, silicon dioxide, and talc into the mixer and mix for 30 minutes;

[0064] (3) After shutdown, add magnesium stearate and mix for 15-20 minutes;

[0065] (4) Sampling and testing the content and content uniformity of intermediate products, and tableting;

[0066] (5)...

Embodiment 3

[0067] Example 3 Perindopril tert-butylamine salt, eplerenone compound tablet and preparation 3

[0068] prescription:

[0069] Element Dosage Perindopril tert-butylamine salt 2.0mg Eplerenone 25mg lactose 40mg microcrystalline cellulose 20mg Croscarmellose Sodium 3.5mg Sodium Lauryl Sulfate 3.5mg Magnesium stearate 2.0mg silica 2.0mg talcum powder 2mg total 100mg

[0070] Preparation:

[0071] (1) Perindopril tert-butylamine salt and eplerenone were mixed with microcrystalline cellulose, lactose and sodium lauryl sulfate in equal increments respectively;

[0072] (2) After mixing, put the above mixture, croscarmellose sodium, silicon dioxide, and talc into the mixer and mix for 30 minutes;

[0073] (3) After shutdown, add magnesium stearate and mix for 15-20 minutes;

[0074] (4) Sampling and testing the content and content uniformity of intermediate products, and tableting;

[0075] (5)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a compound antihypertensive medicine composition. Per unit preparation of the compound antihypertensive medicine composition contains perindopril tert-butylamine salt and eplerenone. Damage caused by aldosterone can still happen though ACEI and ARB treatment is fully conducted. Thus, it is necessary to adopt an aldosterone receptor antagonist to treat hypertension. Perindopril tert-butylamine salt and eplerenone are compounded according to the mechanism, animal test observation proves that combined use of the angiotensin converting enzyme inhibitor, namely perindopril tert-butylamine salt, and eplerenone influences nitric oxide bioavailability and spontaneous atherosclerosis of experimental rabbits; bioavailability of nitric oxide can be effectively improved. Perindopril tert-butylamine salt and eplerenone are used together so as to improve living quality and reduce the death rate of patients suffering from severe heart failures and myocardial infarction.

Description

technical field [0001] The invention belongs to the technical field of medicine development, and in particular relates to a compound antihypertensive pharmaceutical composition. Background technique [0002] Hypertension is a clinical syndrome mainly manifested by elevated systemic circulation arteries and peripheral small arterial resistance accompanied by varying degrees of increased cardiac output and blood volume. Clinically divided into two types of primary and secondary. [0003] Cardiovascular system disease has always been a disease of widespread concern in my country and the world, and it is also one of the areas where various pharmaceutical companies invest heavily in research and development and the market competition is the most intense. [0004] The main types of antihypertensive drugs are: α-receptor blockers (not commonly used, recommended as the first choice), β-receptor blockers, diuretics, calcium antagonists, angiotensin converting enzyme inhibitors (ACEI...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/05A61K9/20A61K47/38A61P9/12A61K31/585
Inventor 贺亁辉杜芳张耀华潘鸿燕张鑫
Owner SHANGHAI PHARMA DONGYING JIANGSU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com